DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the GUFIC BIOSCIENCES LTD. (GUFICBIO) share price today?

GUFIC BIOSCIENCES LTD. (GUFICBIO) is trading at ₹381.9 on the NSE, down 1.65% on the day. Source: DocStoX.

What is the PE ratio of GUFIC BIOSCIENCES LTD.?

GUFIC BIOSCIENCES LTD. has a price-to-earnings (PE) ratio of 54.8 in the Healthcare sector.

What is the market capitalisation of GUFIC BIOSCIENCES LTD.?

GUFIC BIOSCIENCES LTD. has a market capitalisation of approximately ₹3,835 crore.

GUFIC BIOSCIENCES LTD.

GUFICBIO·NSE·Healthcare

₹381.90▼ -6.40 (-1.65%)

Healthcare · Pharmaceuticals

Revenue under pressure recently

Day₹378.30

₹389.45

52W₹268

₹44863%

Open

₹388.30

High

₹389.45

Low

₹378.30

Prev Close

₹388.30

Volume

69.3K

VWAP

₹381.80

Snapshot

Key fundamentals

Market Cap

₹3,835 Cr

P/E Ratio

54.79Expensive

P/B Ratio

5.84

EPS

₹6.97

Book Value

₹66.31

ROE

11.59%Average

ROCE

13.00%Decent

Dividend Yield

0.03%

Debt / Equity

0.61Moderate

Face Value

₹1.00

52W High

₹448.00

52W Low

₹268.00

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

None moatHigh uncertainty

Fair value estimate

₹74

▼ 80.7%downside

Trading at ₹382 — 81% above our estimate

BearFair valueBull

₹63₹74₹102

/100

Business quality — Watch the fundamentals

Growth 0Profitability 35Efficiency 13Valuation 35

Plain English

Our view

Revenue under pressure recently
Promoters hold a controlling stake
Revenue has been shrinking

Strengths

Promoters hold a controlling stake

Risks

Revenue has been shrinking
Fundamental red flags (Piotroski 3/9)

How we got there

Fair value methods

Residual income

12% ROE fading to 13% over ~3 yrs, on ₹66 book

₹66

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹102

Analyst target

No analyst coverage

—

Blended fair value₹74

What the numbers say

Investment thesis

Bull case

Promoters hold a controlling stake

Bear case

Revenue has been shrinking
Fundamental red flags (Piotroski 3/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

54.8Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

11.6%Average

Above 15% is considered healthy for Indian equities

ROCE

13.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.61Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹3,835 Cr

P/B

5.84

EPS

₹6.97

Div Yield

0.03%

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Expensive

P/E 54.8×

Growth

Steady

+11% rev CAGR

Profitability

Modest

11.6% ROE

Financial health

Comfortable

D/E 0.61

Momentum

N/A

No technicals

Today

Trading activity

Delivery %46.2%

Turnover₹264.69L Cr

Trades2,424

VWAP₹381.80

Face value₹1.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+11.0%

+14.1%

10Y

+16.7%

Profit

-7.1%

+7.8%

10Y

+24.8%

EPS

—

10Y

—

Profile

Cons

Stock is trading at 5.92 times its book value
Company has a low return on equity of 13.5% over last 3 years.
Dividend payout has been low at 1.40% of profits over last 3 years

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

73%

Promoter

Promoters

72.5%0.00

Public

23.2%-0.07

FII / FPI

0.4%-0.02

DII

3.8%+0.09

Total shareholders

29,223-1,139 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter72.50%

FII0.42%

DII3.83%

Public23.23%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Gufic Biosciences Limited is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products.